BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Deals

  Top I&I Deals So Far in 2024

  The size of the global immunology market is projected to nearly double by 2032 to a quarter of a trillion dollars. Here are this year’s standout deals in the space.

  August 7, 2024

   · 

  5 min read

   · 

  Mollie Barnes
• 

  Podcast

  Pharma Campaign Contributions, Vaccine Hiccups and Lykos’ Moment of Truth

  With U.S. election season now in full swing, BioSpace looks at pharmaceutical-associated campaign contributions. Plus, Q2 earnings, Adaptimmune’s big approval, an anticipated FDA decision on an MDMA-assisted treatment and more.

  August 7, 2024

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Earnings

  Novo Lowers Full-Year Profit Guidance Amid Disappointing Q2 Semaglutide Sales

  Novo Nordisk’s semaglutide brands Ozempic and Wegovy fell short of analyst expectations in the second quarter, mainly held back by supply headwinds. The company’s shares dropped more than 7% in Wednesday morning trading.

  August 7, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  As Election Nears, Pharma Hedges Campaign Contribution Bets

  Lobbying groups and individuals connected with the industry are supporting candidates from both parties, with a particular focus on the future of the 340B discount program and pharmacy benefit managers.

  August 7, 2024

   · 

  4 min read

   · 

  Tyler Patchen
• 

  Rare Diseases

  Biopharma Entrepreneurs Make Business Case for Personalized Genetic Medicines

  Experts say the time is now to develop and provide widespread access to genetic medicines for the rarest diseases. What’s more, they say it is a moral imperative.

  August 7, 2024

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Vaccines

  Gardasil Chinese Distribution Issue Still a Mystery to Analysts

  After Merck noted the issue in its Q2 earnings call without providing specifics, analysts are left in the dark about the HPV vaccine’s future in China.

  August 7, 2024

   · 

  3 min read

   · 

  Tyler Patchen
• 

  Earnings

  Amgen Touts Q2 Growth Bolstered by Horizon Buy, Promising Obesity Pipeline

  The company is projecting that future growth will be driven by geographic and label expansions for its rare disease assets, as well as potential approvals in obesity.

  August 7, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Supply chain

  Novo Nearly Catches Up to Lilly, Clears Ozempic and Wegovy from FDA Drug Shortage List

  A day after Eli Lilly’s obesity and weight-loss therapies were removed from the regulator’s database, Novo Nordisk also made strides in boosting the supply of all but one of semaglutide’s shortages.

  August 7, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma

  Servier Pharmaceuticals’ vorasidenib on Tuesday secured the FDA’s green light for the treatment of patients with grade 2 gliomas carrying mutations in the IDH gene.

  August 7, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

  August 7, 2024

   · 

  7 min read